Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases.
The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases including Parkinson’s, a priority indication for the company. The company also aims to expand its proprietary platform to include other diseases, such as other neurodegenerative diseases, macular degeneration, fibrosis and cancer.
Nitrome’s novel approach was featured in the article entitled, “Slowing Down the Effects of Neurological Disorders Using Nitrases.”
It’s about working with the right team of people to discover, innovate, and create new therapies to improve lives.
